Welcome!

News Feed Item

Milestone Scientific Announces Financial Results for the Second Quarter of 2014

Revenue Increases 10.0% to $2.5 Million; Domestic Handpiece Sales Increase 22.0%; International Handpiece Sales Increase 20.1%; Domestic Sales Increase 9.3%; International Sales Increase 10.7%; Shareholders' Equity Increases to $15.3 Million

LIVINGSTON, NJ--(Marketwired - August 14, 2014) - Milestone Scientific Inc. (OTCQB: MLSS), a medical R&D company that designs, patents, incubates and commercializes a growing portfolio of innovative injection technologies, today announced financial results and provided a business update for the three and six months ended June 30, 2014.

Leonard Osser, Chief Executive Officer of Milestone Scientific stated, "We are making progress advancing our epidural and intra-articular instruments through the regulatory process. We have developed a broad platform of computer-controlled injection technologies serving a wide array of medical applications and we look forward to announcing additional medical instruments later this year."

"We are also adding strategic resources that we believe will help us advance both our dental and medical instruments. We recently announced the appointment of Gian Domenico Trombetta as Chief Executive Officer of the dental division. He has an impressive track record leading high growth companies across a broad range of industries. We also announced the appointment as Marketing Consultant of Steven Robins, who has overseen the marketing and operations for billion dollar divisions of Fortune 500 healthcare and consumer product companies. Both executives bring valuable industry contracts and expertise."

Mr. Osser continued, "Total revenue for the second quarter of 2014 increased 10.0% to $2.5 million. We achieved a 22.0% increase in domestic handpiece sales and a 20.1% increase in international handpiece sales. This growth in domestic handpieces is due in part to the greater transparency we have with our customers, through our exclusive distributor Aseptico. We are able to establish direct relationships with the dentists and train them properly so they can utilize a greater number of handpieces per year."

"During the second quarter, we announced a $10 million financing which enables us to accelerate the development of additional medical instruments based on our patented CompuFlo and Dynamic Pressure Sensing technologies. Future medical applications of our technologies which will benefit from this investment could include colorectal surgery, podiatry, dermatology, orthopedics, nasal and sinus surgery, and cosmetic surgery, among others. The financing also allows us to more aggressively market and sell our dental instruments and handpieces in the United States and worldwide. As a result of this financing, we now have over $15 million of shareholders' equity. Given the strength of our balance sheet and continued positive cash flow from operations, we believe we are well positioned in the months and years ahead."

Revenue for the three months ended June 30, 2014 was $2.5 million versus $2.3 million for the second quarter of 2013. Domestic instrument sales decreased by $33,376 or 8.7% in the second quarter of 2014 versus the same period in 2013 due to lower distributor purchase prices for the STA instruments for a limited time period. The strategy is to facilitate the deployment of the STA instruments at a faster pace, thus generating recurring handpiece revenue. Domestic handpiece sales increased by $146,527, or 22.0% in 2014 over 2013. On the international front, instrument sales decreased by $34,677 or 9.4% in the second quarter of 2014 versus the same period in 2013. International handpiece sales increased by $162,758 or 20.1% in the second quarter of 2014 versus 2013. Gross profit for the second quarter of 2014 was $1.6 million or 63.6% of revenue versus $1.5 million or 67.3% of revenue for the second quarter of 2013. The decrease in gross margin reflected the lower pricing strategy on the instruments to drive handpiece sales. Operating income for the second quarter of 2014 was $47,507 versus an income of $151,113 for the second quarter of 2013. Net loss for the second quarter of 2014 was ($169,457), or $(0.01) per share, versus an income of $74,009 or $0.00 per share for the comparable period in 2013. Net loss for the second quarter of 2014 includes a Loss on Earnings from Medical Joint Venture of ($213,193) compared to ($47,093) for the three months ended June 30, 2013. Also, the June 30, 2013 net income included the positive impact of the reversal of the bad debt reserve for uncollectable accounts in 2013 that did not occur in 2014.

Revenue for the six months ended June 30, 2014 was $5.1 million versus $4.8 million for the six months ended June 30, 2013. In the domestic market, total revenue was approximately equal in both periods. On the international front, total revenue increased by $345,924 to $2.7 million versus $2.4 million for the same period in 2013. Gross profit for the six months ended June 30, 2014 was $3.3 million or 65.0% of revenue versus $3.2 million or 67.4% of revenue for the six months ended June 30, 2013. Operating income for the six months ended June 30, 2014 was $376,753 versus an income of $318,874 for the six months ended June 30, 2013. Net income for the six months ended June 30, 2014 was $25,377, or $0.00 per share, versus an income of $224,754, or $0.01 per share, for the comparable period in 2013. Net income for the six months ended June 30, 2014 includes a Loss on Earnings from Medical Joint Venture of ($343,716) compared to ($47,093) for the same period last year.

Milestone's executive management team will host a teleconference on Thursday, August 14, 2014 at 8:30 A.M. Eastern Time to discuss the company's financial results. 

The conference call will be available via telephone by dialing toll free 1-888-359-3627 and entering the pass code 8220117 or on the company's website at www.milestonescientific.com. For those unable to participate at that time, a replay of the call will be archived on the company's website or can be accessed by dialing 1-888-203-1112 and entering the pass code 8220117. The replay will be available for 90 days.

About Milestone Scientific Inc.

Milestone Scientific Inc. (MLSS) is a leading medical research and development company that designs and patents innovative injection technology. Milestone's computer-controlled systems make injections precise, efficient, and virtually painless. For more information please visit our website: www.milestonescientific.com.

Safe Harbor Statement
This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report for the year ended December 31, 2013. The forward looking statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

(tables follow)

                                                                            
                         MILESTONE SCIENTIFIC INC.                          
                     CONDENSED STATEMENTS OF OPERATIONS                     
                                (Unaudited)                                 
                                                                            
                          Three Months Ended June    Six Months Ended June  
                                    30,                       30,           
                         ------------------------  ------------------------ 
                             2014         2013         2014         2013    
                         -----------  -----------  -----------  ----------- 
                                                                            
Product sales            $ 2,506,932  $ 2,278,235  $ 5,127,766  $ 4,767,778 
Cost of products sold        912,406      744,108    1,795,403    1,556,152 
                         -----------  -----------  -----------  ----------- 
  Gross profit             1,594,526    1,534,127    3,332,363    3,211,626 
                         -----------  -----------  -----------  ----------- 
                                                                            
Selling, general and                                                        
 administrative expenses   1,517,854    1,340,129    2,910,724    2,728,031 
Research and development                                                    
 expenses                     29,165       42,885       44,885      164,722 
                         -----------  -----------  -----------  ----------- 
Total operating expenses   1,547,019    1,383,014    2,955,609    2,892,752 
                         -----------  -----------  -----------  ----------- 
Income from operations        47,507      151,113      376,754      318,874 
Other income (expenses)                                                     
  Other income                     -            -            -       17,543 
  Interest income                                                           
   (expense)                     635      (30,011)         161      (64,569)
  Loss from Medical                                                         
   Joint Venture            (213,193)     (47,093)    (343,716)     (47,093)
  Loss from Education                                                       
   Joint Venture              (4,406)           -       (7,822)           - 
                         -----------  -----------  -----------  ----------- 
    Total other                                                             
     expenses, net          (216,964)     (77,104)    (351,377)     (94,119)
                         -----------  -----------  ===========  =========== 
Net (loss) income                                                           
 applicable to common                                                       
 stockholders            $  (169,457) $    74,009  $    25,377  $   224,754 
                         ===========  ===========  ===========  =========== 
                                                                            
Net (loss) income per                                                       
 share applicable to                                                        
 common stockholders -                                                      
  Basic                  $     (0.01) $      0.00  $      0.00  $      0.01 
                         ===========  ===========  ===========  =========== 
  Diluted                $     (0.01) $      0.00  $      0.00  $      0.01 
                         ===========  ===========  ===========  =========== 
Weighted average shares                                                     
 outstanding and to be                                                      
 issued -                                                                   
  Basic                   20,246,281   16,744,951   19,196,919   16,765,602 
                         ===========  ===========  ===========  =========== 
  Diluted                 20,246,281   17,056,219   22,206,942   17,124,936 
                         ===========  ===========  ===========  =========== 
                                                                            
                                                                            
                          MILESTONE SCIENTIFIC INC.                         
                          CONDENSED BALANCE SHEETS                          
                                                                            
                                                   June 30,    December 31, 
                                                     2014          2013     
                                                  (Unaudited)               
                                                 ------------  ------------ 
                     ASSETS                                                 
Current Assets:                                                             
  Cash and cash equivalents                      $  1,121,721  $  1,147,198 
  Treasury Bills                                    9,498,498             - 
  Accounts receivable, net of allowance for                                 
   doubtful accounts of $5,000 as of June 30,                               
   2014 and $5,000 as of December 31, 2013          1,443,386     1,532,856 
  Inventories                                       1,964,390     1,321,652 
  Advances on contracts                             1,454,807       727,478 
  Prepaid expenses and other current assets           161,560       150,451 
                                                 ------------  ------------ 
    Total current assets                           15,644,362     4,879,635 
Advances on contracts                                 218,875     1,580,874 
Investment in Milestone Medical Inc                   760,750       924,115 
Investment in Milestone Education LLC                  34,261        42,082 
Furniture, Fixtures & Equipment net of                                      
 accumulated depreciation of $454,818 as of June                            
 30, 2014 and $476,884 as of December 31, 2013         38,153        23,988 
Patents, net of accumulated amortization of                                 
 $537,687 as of June 30, 2014 and $498,502 as of                            
 December 31, 2013                                    552,550       591,735 
Other assets                                           12,917        12,917 
                                                 ------------  ------------ 
      Total assets                               $ 17,261,868  $  8,055,346 
                                                 ============  ============ 
                                                                            
      LIABILITIES AND STOCKHOLDERS' EQUITY                                  
Current Liabilities:                                                        
  Accounts payable                               $    983,972  $  2,020,368 
  Customer advances                                   209,000             - 
  Accrued expenses and other payables                 754,538       515,133 
                                                 ------------  ------------ 
    Total current liabilities                       1,947,510     2,535,501 
                                                 ------------  ------------ 
                                                                            
Commitments and Contingencies                                               
                                                                            
Stockholders' Equity                                                        
  Series A Convertible Preferred Stock, par                                 
   value $.001, authorized 5,000,000 shares,                                
   7,000 and zero shares issued and outstanding,                            
   respectively                                  $          7  $          - 
  Common stock, par value $.001; authorized                                 
   50,000,000 shares; 21,074,786 shares issued                              
   875,322 shares to be issued and 21,041,453                               
   shares outstanding as of June 30, 2014;                                  
   17,759,540 shares issued, 1,839,930 shares to                            
   be issued, and 17,726,207 shares outstanding                             
   as of December 31, 2013                             21,949        19,599 
  Additional paid-in capital                       76,443,979    66,677,200 
  Accumulated deficit                             (60,240,061)  (60,265,438)
  Treasury stock, at cost, 33,333 shares             (911,516)     (911,516)
                                                 ------------  ------------ 
    Total stockholders' equity                     15,314,358     5,519,845 
                                                 ------------  ------------ 
      Total liabilities and stockholders' equity $ 17,261,868  $  8,055,346 
                                                 ============  ============ 
                                                                            

Contact:
David Waldman or Natalya Rudman
Crescendo Communications, LLC
Email: [email protected]
Tel: 212-671-1020

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Latest Stories
Enterprises are adopting Kubernetes to accelerate the development and the delivery of cloud-native applications. However, sharing a Kubernetes cluster between members of the same team can be challenging. And, sharing clusters across multiple teams is even harder. Kubernetes offers several constructs to help implement segmentation and isolation. However, these primitives can be complex to understand and apply. As a result, it’s becoming common for enterprises to end up with several clusters. Thi...
"Infoblox does DNS, DHCP and IP address management for not only enterprise networks but cloud networks as well. Customers are looking for a single platform that can extend not only in their private enterprise environment but private cloud, public cloud, tracking all the IP space and everything that is going on in that environment," explained Steve Salo, Principal Systems Engineer at Infoblox, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Conventio...
"Cloud Academy is an enterprise training platform for the cloud, specifically public clouds. We offer guided learning experiences on AWS, Azure, Google Cloud and all the surrounding methodologies and technologies that you need to know and your teams need to know in order to leverage the full benefits of the cloud," explained Alex Brower, VP of Marketing at Cloud Academy, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clar...
In his session at 21st Cloud Expo, Carl J. Levine, Senior Technical Evangelist for NS1, will objectively discuss how DNS is used to solve Digital Transformation challenges in large SaaS applications, CDNs, AdTech platforms, and other demanding use cases. Carl J. Levine is the Senior Technical Evangelist for NS1. A veteran of the Internet Infrastructure space, he has over a decade of experience with startups, networking protocols and Internet infrastructure, combined with the unique ability to it...
The question before companies today is not whether to become intelligent, it’s a question of how and how fast. The key is to adopt and deploy an intelligent application strategy while simultaneously preparing to scale that intelligence. In her session at 21st Cloud Expo, Sangeeta Chakraborty, Chief Customer Officer at Ayasdi, provided a tactical framework to become a truly intelligent enterprise, including how to identify the right applications for AI, how to build a Center of Excellence to oper...
"IBM is really all in on blockchain. We take a look at sort of the history of blockchain ledger technologies. It started out with bitcoin, Ethereum, and IBM evaluated these particular blockchain technologies and found they were anonymous and permissionless and that many companies were looking for permissioned blockchain," stated René Bostic, Technical VP of the IBM Cloud Unit in North America, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Conventi...
Gemini is Yahoo’s native and search advertising platform. To ensure the quality of a complex distributed system that spans multiple products and components and across various desktop websites and mobile app and web experiences – both Yahoo owned and operated and third-party syndication (supply), with complex interaction with more than a billion users and numerous advertisers globally (demand) – it becomes imperative to automate a set of end-to-end tests 24x7 to detect bugs and regression. In th...
In his session at 21st Cloud Expo, James Henry, Co-CEO/CTO of Calgary Scientific Inc., introduced you to the challenges, solutions and benefits of training AI systems to solve visual problems with an emphasis on improving AIs with continuous training in the field. He explored applications in several industries and discussed technologies that allow the deployment of advanced visualization solutions to the cloud.
Widespread fragmentation is stalling the growth of the IIoT and making it difficult for partners to work together. The number of software platforms, apps, hardware and connectivity standards is creating paralysis among businesses that are afraid of being locked into a solution. EdgeX Foundry is unifying the community around a common IoT edge framework and an ecosystem of interoperable components.
Agile has finally jumped the technology shark, expanding outside the software world. Enterprises are now increasingly adopting Agile practices across their organizations in order to successfully navigate the disruptive waters that threaten to drown them. In our quest for establishing change as a core competency in our organizations, this business-centric notion of Agile is an essential component of Agile Digital Transformation. In the years since the publication of the Agile Manifesto, the conn...
"MobiDev is a software development company and we do complex, custom software development for everybody from entrepreneurs to large enterprises," explained Alan Winters, U.S. Head of Business Development at MobiDev, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
Large industrial manufacturing organizations are adopting the agile principles of cloud software companies. The industrial manufacturing development process has not scaled over time. Now that design CAD teams are geographically distributed, centralizing their work is key. With large multi-gigabyte projects, outdated tools have stifled industrial team agility, time-to-market milestones, and impacted P&L stakeholders.
"ZeroStack is a startup in Silicon Valley. We're solving a very interesting problem around bringing public cloud convenience with private cloud control for enterprises and mid-size companies," explained Kamesh Pemmaraju, VP of Product Management at ZeroStack, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
"Space Monkey by Vivent Smart Home is a product that is a distributed cloud-based edge storage network. Vivent Smart Home, our parent company, is a smart home provider that places a lot of hard drives across homes in North America," explained JT Olds, Director of Engineering, and Brandon Crowfeather, Product Manager, at Vivint Smart Home, in this SYS-CON.tv interview at @ThingsExpo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
"Akvelon is a software development company and we also provide consultancy services to folks who are looking to scale or accelerate their engineering roadmaps," explained Jeremiah Mothersell, Marketing Manager at Akvelon, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.